- Home
- ALV vs VRNA Comparison
ALV vs VRNA Comparison
Compare ALV & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- VRNA
- Stock Information
- Founded
- ALV 1953
- VRNA 2005
- Country
- ALV Sweden
- VRNA United Kingdom
- Employees
- ALV N/A
- VRNA N/A
- Industry
- ALV Auto Parts:O.E.M.
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- VRNA Health Care
- Exchange
- ALV Nasdaq
- VRNA Nasdaq
- Market Cap
- ALV 9.1B
- VRNA 8.3B
- IPO Year
- ALV 1997
- VRNA 2017
- Fundamental
- Price
- ALV $124.07
- VRNA $105.91
- Analyst Decision
- ALV Buy
- VRNA Buy
- Analyst Count
- ALV 10
- VRNA 11
- Target Price
- ALV $122.10
- VRNA $114.10
- AVG Volume (30 Days)
- ALV 543.8K
- VRNA 1.3M
- Earning Date
- ALV 10-17-2025
- VRNA 08-06-2025
- Dividend Yield
- ALV 2.74%
- VRNA N/A
- EPS Growth
- ALV 21.77
- VRNA N/A
- EPS
- ALV 9.16
- VRNA N/A
- Revenue
- ALV $10,462,000,000.00
- VRNA $221,673,000.00
- Revenue This Year
- ALV $3.65
- VRNA $896.59
- Revenue Next Year
- ALV $4.08
- VRNA $77.56
- P/E Ratio
- ALV $13.55
- VRNA N/A
- Revenue Growth
- ALV N/A
- VRNA N/A
- 52 Week Low
- ALV $75.49
- VRNA $24.50
- 52 Week High
- ALV $125.82
- VRNA $105.98
- Technical
- Relative Strength Index (RSI)
- ALV 68.02
- VRNA 69.13
- Support Level
- ALV $118.79
- VRNA $105.23
- Resistance Level
- ALV $125.82
- VRNA $105.85
- Average True Range (ATR)
- ALV 1.97
- VRNA 0.26
- MACD
- ALV 0.55
- VRNA -0.33
- Stochastic Oscillator
- ALV 87.08
- VRNA 91.14
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.